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Abstract— Nowadays, the concept of personalized therapy gains 
momentum. Pharmacogenomics, which represents a first answer 
to these needs, has the drawback of neglecting some variations of 
therapy response due to non-genetic factors. The aim of this 
paper is to investigate the feasibility of a non-genetic approach to 
personalized therapy, via the point-of-care drug monitoring in 
biological fluids with electrochemical biosensors. The proposed 
biosensor is based on the use of P450 enzymes as probe 
molecules, thanks to their key role in human metabolism. 
Multiwalled carbon nanotubes are used to enhance biosensor 
sensitivity. Results show how the proposed system is capable to 
detect drug amounts within the corresponding pharmacological 
ranges in human serum. 
Keywords – P450, personalized therapy, electrochemistry, 
human serum. 
I. INTRODUCTION 
At present, the most common clinical practice is the so 
called trial and error medicine [1]: according to the symptoms, 
a drug therapy is prescribed, and if it is not effective, or has 
significant side effects, it is modified. This approach, which is 
time consuming and expensive for both the patient and the 
health care system, is beneficial only to 20-50% of individuals 
while 7% experience severe adverse drug reactions [2]. 
Breakthrough targeted therapies could save many lives and a 
great deal of money. Pharmacogenomics, which considers the 
unique patient’s genetic polymorphism, represents a first step 
towards personalized medicine. However, lifestyle and drug 
interactions, which cannot be predicted with genetics, also play 
an important role in influencing the drug response.  
A system based on the direct drug monitoring in the 
patient’s blood represents a more accurate alternative to the 
pharmacogenomics. P450 proteins represent good candidates 
for the realization of biosensors for drug detection, since they 
account for the 75% of body metabolism [3], and often mediate 
the rate-limiting steps in the biotransformation of xenobiotics 
[4]. Biosensors based on P450s have already been proposed [4-
6]; however, they were always tested in artificial buffers. In 
this work we propose a biosensor based on carbon nanotubes 
(CNT) and two different cytochrome P450 isoforms, 3A4 and 
2C9. These protein isoforms can detect drugs in undiluted 
human serum. The integration of carbon nanotubes greatly 
improves the sensor performance [7-9], while CYP 3A4 and 
2C9 are chosen because they represent the two most important 
isoforms involved in drug metabolism [4, 10]. This sensor is an 
alternative as compared to traditional drug essay techniques, 
such as spectrophotometry and chromatography, which usually 
require sample dilution. 
II. MATERIAL AND METHODS 
A. Reagents 
Carbon paste screen-printed electrodes (model DRP-110 
and DRP-110 CNT) were purchased from Dropsens. 
Cytochrome P450 3A4 and 2C9 microsomes were purchased 
from Sigma-Aldrich and used without further purification. 
Cyclophosphamide (CP) was purchased from Sigma and 
diluted in PBS 100mM pH 7.4 to the working concentrations. 
Naproxen (NAP) was purchased from sigma and diluted in 
ethanol to the working concentrations. Multi walled carbon 
nanotubes (MWCNT - diameter 10 nm, length 1-2 μm, COOH 
content 5 %) were bought in powder (95% purity) from 
DropSens (Spain), diluted in chloroform to the concentration of 
1 mg/ml [4] and then sonicated for 20 minutes in order to break 
macro-aggregates. Human serum was purchased from Lonza 
and used without any dilution.  
B. Electrodes preparation 
The electrodes were made of a graphite working electrode 
(area, 12.56 mm2), a graphite counter electrode and an 
Ag/AgCl reference electrode. The working electrode area was 
12.56 mm2 while the total area of the cell was 22 mm2. CNT 
nano-structuring was obtained by gradually dropping 30 μl of 
CNT solution onto the working electrode and waiting until 
complete evaporation of the chloroform. Electrode 
functionalization was obtained by drop cast of P450 solutions 
onto the working electrode and incubation at 4ºC overnight. 
The excess of cytochrome was then removed by washing with 
milliQ water. 
C. SEM measurement 
Morphological analysis of the structured and functionalized 
electrodes was carried out with Scanning Electron Microscopy 
(SEM). A Zeiss SUPRA 40 SEM instrument was used to 
acquire images for bare electrodes, electrodes structured with 
carbon nanotubes, and electrodes functionalized with the 
cytochrome P450. Images were acquired in 5-20 kV range. 
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Figure 1.  SEM image drop cast MWCNT onto the working electrode.  
D. Electrochemical measurement 
The electrochemical response of the electrodes was 
investigated by cyclic voltammetry under aerobic conditions. 
Voltammograms were acquired using a Versastat 3 potentiostat 
(Princeton Applied Technologies). The electrode was covered 
with 100 μl of PBS 100 mM at pH 7.4 or serum. Drug samples 
were added in drops of 1 μl. The cyclic voltammograms were 
acquired with potential sweeps between -600 and +300 mV vs 
Ag/AgCl at a scan rate of 20 mV/sec. Peak current values were 
then extracted according to the procedure reported in [8]. 
 
III. RESULTS 
A. Electrodes Nano-Structuring and Functionalization 
The SEM image analysis proved that the screen-printed 
electrode surface is highly-corrugated at the nano-scale (data 
not shown). Surface corrugation widely changed after the 
structuring with carbon nanotubes. Fig. 1 shows carbon fibers 
randomly organized onto the screen-printed carbon 
 
 
Figure 3.  Current and potential variation of  P450 versus different electrode 
nano-structuring.   
 
Figure 2.  SEM image drop cast MWCNT  and P450 microsomes onto the 
working electrode. 
paste surface, as also shown in other works [11,12] . The fiber 
has thicknesses ranging from 8 nm up to 20 nm. These values 
are coherent with the average carbon nanotube diameter 
declared by the producer, 10nm. After bio-functionalization 
with the P450 microsomes, fiber size increased to 25 - 48 nm, 
as shown in Fig. 2. 
B. Sensitivity improvement by Electrode Nano-Structuring 
The data obtained from SEM images lead to investigations 
of the most appropriate CNT nanostructuration. We compared 
the current peaks obtained from cytochrome P450 drop cast 
onto bare graphite, a commercial screen-printed with CNT 
embedded in the graphite paste, and an electrode structured by 
us with 30 μl of drop cast CNT. Fig. 3 shows the average 
values obtained from the three different electrodes. Drop cast 
CNT gave the best results in terms of current intensity and 
reproducibility of results. Peak current increased of 116% 
compared to the bare electrode and 50% respect to the 
embedded CNT. Standard deviations in current and potential 
are also lower, which demonstrate increased reproducibility of 
measurements.  
C. CYP3A4 response to Cyclophosphamide 
The biosensor was tested in sensing Cyclophosphamide 
(CP), a chemotherapy drug used for treatment of lymphomas, 
some forms of leukemia and some solid tumors.  P450 peak 
current was first acquired in absence of drugs (blank), and then, 
in presence of CP in concentrations of 100, 200, 300, 400 and 
500 μM. The related current values were subtracted to the 
blank, in order to monitor the effect of the drug addiction. Fig. 
4 shows the average current values obtained in serum and PBS. 
Error bars represent the standard deviation between the 
electrodes. The sensor performance is very close for the two 
buffers: the measured sensitivity resulted in 0.06 nA/μM mm-2 
in case of PBS and 0.04 nA/μM mm-2 in case of serum. For 
both media, the average current increase between blank and CP 
100 μM was 0.13 μA, a value 40% higher than that between 
two subsequent drug concentrations. Peak increase becomes 
smaller for higher concentrations of CP.  
 Figure 4.  Variation of CYP3A4 peak current at different concentrations of 
cyclophosphamide. The plot shows the difference between the current in 
presence of the drug and the blank. 
D. CYP2C9 response to Naproxen 
The biosensor was tested in sensing Naproxen (NAP), a 
non-steroidal anti-inflammatory drug commonly used for pain 
reduction, fever, inflammation and stiffness. P450 peak current 
was first acquired in absence of the drug (blank) and then, in 
presence of NAP in concentrations of 100, 200, 300, 400 and 
500 μM. The resultant current values were subtracted from the 
blank, in order to monitor the effect of the drug addiction. Fig. 
5 shows the current values obtained in serum and PBS from a 
single electrode. Error bars represent the standard deviation in 
measurements with the same electrode. Measured sensitivities 
differ of one order of magnitude in the different buffers: 0.53 
nA/ μM mm-2 in case of PBS and 0.05 nA/ μM mm-2 in case of 
serum. In the latter case, the value is comparable with 
sensitivity obtained with the CYP3A4. The sensor detection 
limit was 200 μM for both media. 
 
 
Figure 6.  SEM image of screen printed electrode DRP110-CNT, reprinted 
form the constructor’s technical data-sheet  [12] 
 
Figure 5.  Variation of CYP2C9 peak current at different concentrations of 
Naproxen. The plot shows the difference between the current in presence of 
the drug and the blank. 
IV. DISCUSSION 
A. Electrode nanostructuring 
SEM images showed an average increase of 20 nm after the 
drop cast of P450 microsomes. Taking into account that the 
cytochrome P450 is a globular protein with size below 10 nm, 
this means that a single protein layer is surrounding each single 
carbon nanotube fiber. Therefore, each probe protein is in 
direct contact with the nanotube surface accounting for a direct 
electron-transfer between CNT and proteins. Increased 
sensitivity of drop-casted CNT can be due to the three-
dimensional architecture of the nano-structuring. SEM images 
reported from electrode constructor [13] and from [14] show 
that CNT embedded in carbon paste change the texture of the 
carbon surface, allowing a deeper penetration of the 
electrolytes and a larger amount of probe proteins, as shown in 
Fig. 6. Our data shows how the drop cast nanotubes present a 
less compact texture, which allows us to increase the amount of 
probes adsorbed. 
B. Drug detection 
In case of CYP 3A4, the optimal concentration window for 
cyclophosphamide sensing, can be placed at lower 
concentrations as compared to the maximum one. This is due 
to the diminishing of peak increase with higher drug amounts 
and to the current gap between the blank and the first drug 
concentration. On the other hand, the CP pharmacokinetic 
range recorded in the blood during therapies is typically 
between 0 and 77 μM [15]. Luckily, Fig. 4 does not show a 
detection limit. Therefore, further refining the proposed 
biosensor is possible for smaller drug concentrations. An 
additional reason for lowering the operating window is related 
to the enzyme kinetics. If the drug amount is larger than the 
enzyme concentration on the electrode, the rate of catalysis 
approaches asymptotically to a limit value. Since peak current 
depends by the rate at which cytochrome and electrode are 
exchanging electrons, a constant speed of catalysis means 
constant electrons exchange and, therefore, constant current. 
Achieving a response proportional to the drug addiction could 
be possible by lowering the substrate concentration or 
augmenting the quantity of the enzyme drop cast on the 
electrode surface. Data from CYP2C9 reported in Fig. 5 is a 
characterisic example of current response proportional to the 
drug concentration. Results demonstrate that detection limit for 
Naproxen sensing is determined at 200 μM since current 
variations at lower concentration are smaller than the 
acquisition noise. The lower sensitivity achieved in serum is 
attributed to plasma proteins, which can affect the P450 
performance onto the electrodes and can retain drug molecules. 
In case of naproxen for example, it was demonstrated that 
99.7% of compound in the blood is bound to albumin [16], 
therefore effective naproxen concentration at the electrode can 
be lowered due the presence of those complexes. These two 
results show the possibility to accomplish real-time 
electrochemical drug detection in biological buffer due to the 
intrinsic nature of the drug/P450 interactions. However, the 
advantage of a wide substrate range in using P450 proteins is 
also a problem for the unequivocal identification of compounds 
when more than one drug is present in the patient’s blood. 
Different P450 isoforms can have the same drug compound as 
substrate and different drugs can be metabolized by the same 
protein. For example, naproxen is metabolized both by 
CYP2C9 and CYP1A2 [17], or dextromethorphan is a common 
substrate of CYP2D6 and CYP3A families [18].  A general 
approach to this issue is the design of an electrode array 
containing different P450 isoforms, which may be selectively 
queried by choosing the protein combinations that can grant the 
unequivocal identification of a single compound. This principle 
related to irredundant cover problem, has been explained more 
in detail in our previous work [8]. 
 
V. CONCLUSIONS 
In this paper, we demonstrated the feasibility of P450-based 
technology for drug monitoring in human serum for 
personalized therapy. The sensor, based on drop-cast MWCNT 
and two different cytochrome P450 isoforms is capable to 
detect drugs in micromolar concentrations. The amounts 
measured were close to therapeutic range of the considered 
drugs. Applications in drug therapy are therefore feasible. The 
proposed approach has the potential to represent a valid 
alternative to pharmacogenomics methods, since it can account 
for factors that cannot be predicted on the sole genome 
knowledge, such as lifestyle and drugs interactions. We claim 
that such technology can be used to develop point-of-care and 
low cost devices for personalized therapy. The potential socio-
economical relevance of the technology proposed here is high, 
since the possibility to overcome the traditional trial and error 
drug therapy can allow a huge decrease in the medical care 
costs, and reduce the time needed to find the right therapeutic 
regime, improving the quality of the life of the patients. 
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